Document is current
Any future updates will be listed below
-
Authors
Roselli, Sandra https://orcid.org/0000-0003-2998-3760
Satir, Tugce Munise https://orcid.org/0000-0001-9021-1650
Camacho, Rafael https://orcid.org/0000-0003-2325-6407
Fruhwürth, Stefanie https://orcid.org/0000-0003-4035-7330
Bergström, Petra https://orcid.org/0000-0003-1803-165X
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Agholme, Lotta https://orcid.org/0000-0003-3816-7474
-
Funding
Funding for this research was provided by:
University of Gothenburg
Demensfonden
Åhlén-stiftelsen
Gun och Bertil Stohnes Stiftelse
Magnus Bergvalls Stiftelse
Alzheimerfonden
Stiftelsen för Gamla Tjänarinnor
European Research Council (681712)
Vetenskapsrådet (35-02532)
Swedish State Support for Clinical Research (ALFGBG-720931)
- License Information
-
More Information
Article History
Received: 8 December 2022
Accepted: 9 June 2023
First Online: 24 June 2023
Declarations
:
: Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other authors report no conflicts of interest.
